Pergolide Mesylate Tablets

1. Pharmacological studies: Pergolide is a typical central nervous system postsynaptic dopamine receptor agonist, which can significantly inhibit the release of prolactin from the anterior pituitary gland, reduce the serum prolactin content of normal and reserpine rats; reduce the metabolic conversion of dopamine in the rat brain, thereby reducing the content of 3,4-dihydroxyphenylacetic acid in the brain, and cause rats with nigrostriatal damage to produce contralateral rotation reactions; increase the autonomous activity and climbing behavior of mice, cause stereotyped movements in rats and guinea pigs, and counteract spontaneous tremors caused by ventral damage to the midbrain dorsal cover of monkeys. 2. Toxicological studies: The acute toxicity oral LD50 of female mice is 81.8mg/kg, and the oral LD50 of male mice is 61.7mg/kg. The long-term toxicity test of rats after oral administration for 6 months showed that this product can cause a dose-dependent increase in autonomous activity and irritability, slow down the rate of weight gain, and significantly increase the weight of the ovaries of female mice. After stopping the drug, the weight gain rate and ovarian weight returned to normal. This product has no significant effect on the hematology, blood biochemistry, other organs and histopathology of rats. Dogs were given oral administration for three months without obvious toxicity. Microbial reverse mutation test, mouse micronucleus test, in vitro cultured human lymphocyte chromosome aberration test, the results showed that this product has no mutagenic effect. This product did not cause teratogenic effect in mice during the teratogenic sensitive period.

C19H26N2SCH3SO3H

This product is white tablets. The main ingredient of this product is pergolide mesylate.

This product is a dopamine receptor agonist and a synergistic drug for compound levodopa preparations. It is suitable for: 1. Patients with Parkinson's disease and Parkinson's syndrome whose compound levodopa preparations have reduced efficacy or motor dysfunction, such as the on-off phenomenon. It can also be used for early combined treatment. 2. Hyperprolactinemia.

Oral administration. 1. Parkinson's disease: The initial dose is 0.05 mg/day, maintained for 2-3 days; then gradually increase the dose under the guidance of a doctor, increasing by 0.05 mg each time, until the optimal effective dose is reached, and the maximum dose can be increased to 0.2 mg/day, or follow the doctor's advice. 2. Hyperprolactinemia: The initial dose is 0.025-0.05 mg/day, and the dose is adjusted every 2 weeks, with the maximum dose being 0.1-0.15 mg/day, or follow the doctor's advice.

Adverse reactions such as nausea, vomiting, dizziness, fatigue, nasal congestion, skin itching, and constipation may occur. If the adverse reactions are severe, the drug must be discontinued. According to foreign literature reports, some patients have experienced mental symptoms and positional hypotension after taking this product orally; some patients have experienced sinus tachycardia with atrial premature beats.

People who are allergic to this product or other ergot derivatives.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

1. This drug can enhance its antihypertensive effect when used in combination with antihypertensive drugs. 2. The sedative effect is enhanced when used in combination with other central nervous system depressants. 3. When used in combination with levodopa, the incidence of movement disorders in Parkinson's patients increases, and reducing the dosage of levodopa can often alleviate it. 4. Dopamine antagonists can weaken the efficacy of this drug, and the combination of the two should be avoided. 5. Depending on the dosage, any of the following drugs may interact with this drug: droperidol, haloperidol, loxapine, methyldopa, metoclopramide, molindone, papaverine, phenothiazines, and reserpine.

Protect from light, seal tightly, and store in a cool and dry place.

0.25 mg

24 months